quavonlimab,lenvatinib,favezelimab,pembrolizumab
eisai,merck
[]
 seems like the tip of the iceberg- hoping multiplexing t cell transcriptome (inflammatory state) w existing biomarkers (tmb, pd-l1) can help us identify new synergies. terrible to sometimes see lack of effect in nsclc pd-l1 &gt;50% and have no idea why- maybe some clues here.